Lilly takes two shots at the Nectin goal
A second Lilly Nectin-4 ADC features among the latest phase 1 initiations.
IO Biotech looks for an interim injection
The group plays down upcoming interim analysis, but still hopes for accelerated approval.
Merck KGaA’s xevinapant gets SMACked down
One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.
The predictable failure of trilaciclib
The CDK4/6 inhibitor flunks its phase 3 study – a result that should have been foreseen five years ago.
Bristol overtakes Amgen in colorectal
Meanwhile, Bristol’s other competition in this disease looks set to come from China.
ALX looks to surprise again
But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.
